Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen ± GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer
2009-015122-11Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Jan 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of tamoxifen, goserelin, leuprolide and exemestane in breast cancer (3 arms), sponsored by GBG Forschungs. Primary endpoint: Estradiol suppression at 3 months. Started Jan 2012; status: completed.
02
Drugs
tamoxifengoserelinleuprolideexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-015122-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015122-11.